Market Landscaping for Launch Planning

Localizing your global pipeline for Nordic success

The journey from EMA approval to payer acceptance is filled with hurdles. You must secure a recommendation from HTA bodies such as the Danish Medicines Council, identify the right stakeholders, understand local treatment patterns, and demonstrate your product’s value to local HCPs.

We help you adapt your global launch strategy to fit the Nordic reality, removing complexity and saving you valuable time and resources.

360° launch acceleration framework

Launching a new medicinal product or extending indications of existing therapies requires coordination across multiple teams and local market expertise.
Our team of experts in stakeholder insights, market access and RWE supports your journey from approval to payer acceptance and patient treatment.

This diverse expertise ensures your launch process will be covered from a 360° perspective.

Market research as your compass for Nordic success

What are local HCPs’ pain points with current treatments? What unmet needs exist? What is the market maturity and readiness for your product?

Our market research answers these crucial questions, transforming your global launch package into a Nordic success story. Through customized research designs, we uncover rational and emotional drivers influencing key stakeholders.

This pre-launch research should begin one to two years before launch when you receive the global launch package from headquarters. If you think that’s plenty of time; it isn’t. Those 12-24 months can determine whether your product reaches patients or gets stuck in regulatory limbo.

For affiliates in the Nordics managing multiple annual launches, our tactical approach reduces administrative burden, helping your products reach patients faster.

When your product requires changes in diagnosis testing, handling, or patient monitoring, our research helps bridge the gap between current clinical practice and the ideal future clinic. This process worked effectively in our melanoma immunotherapy research, where we uncovered crucial factors influencing treatment decisions. Similarly, our work on hereditary heart conditions identified significant opportunities in a field with minimal recent innovation.

Break through the market access barrier

Positioning your product effectively and highlighting its unique selling points is essential when competing in a crowded market. We understand that many product launches fail to reach even half of their forecasts – outcomes that could be dramatically improved with proper market knowledge, advisory, and data analytics.

Our approach integrates market access planning early in your product journey, ideally starting prior to Phase II clinical trials, ensuring that commercial considerations shape your development strategy. However, we provide support at any stage of your product lifecycle, whether you’re in early development or preparing for an imminent launch.

Success with the Danish Medicines Council or another Nordic HTA board depends on deep local expertise and compelling evidence of your product’s value.

The role of Real-World Evidence

Real-world evidence (RWE) plays a crucial role in your product launch strategy by providing insights that clinical trials alone cannot deliver:

• RWE reveals treatment patterns and adherence, indicating potential barriers for uptake
• RWE documents patient outcomes, strengthening your case for Danish Medicines Council evaluation
• We help identify regions and hospitals most likely to adopt your product quickly
• Our analyses help you understand your total addressable market (TAM) with precision

By leveraging our exclusive access to healthcare registries and the Danish Health Data Authority’s Secure Research Platform (“Forskermaskinen”), we provide evidence-based insights that support your market entry strategy and help you demonstrate your product’s value in real-world settings.

Map out your key opinion leaders who amplify your success

Which HCPs connect patients to new treatments in your field? When launching a product, identifying these clinical influencers who champion innovative approaches is essential. Your field force needs to engage with these key voices, who might not be the most published specialists.

Our Key Opinion Leader solution maps professional networks within your specific disease or treatment area, identifying important healthcare professionals who can support your market access and Health Technology Assessment processes. The analysis provides concrete data on each professional’s market influence, research connections, and publication history.

With this knowledge, you can prioritize your outreach efforts and build relationships with the healthcare professionals who will drive your product’s adoption.

Understand your patient for effective adoption

Success in the crucial early months after launch depends on knowing exactly who your patients are and where to find them. Our two specialized data solutions give you this vital intelligence when you need it most.

• Patient Impact Planner analyzes anonymized patient data to reveal aggregate treatment patterns, geographic distribution, and prescription fulfillment locations. This helps you target pharmacy campaigns and field force efforts precisely during your launch phase.

• Indication Insights tracks market share development by indication, allowing you to monitor your launch progress with specific patient groups. By combining sales data with National Patient Register information, we show you where the highest concentration of relevant patients can be found and adjust your launch strategy accordingly.